Janus Henderson Group PLC Invests $23.44 Million in Monopar Therapeutics Inc. (NASDAQ:MNPR)

Janus Henderson Group PLC bought a new position in Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,046,899 shares of the company's stock, valued at approximately $23,435,000. Janus Henderson Group PLC owned 17.16% of Monopar Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of MNPR. JPMorgan Chase & Co. purchased a new position in Monopar Therapeutics during the 4th quarter valued at about $45,000. Geode Capital Management LLC grew its position in Monopar Therapeutics by 174.4% during the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company's stock valued at $849,000 after purchasing an additional 24,530 shares in the last quarter. ADAR1 Capital Management LLC acquired a new position in Monopar Therapeutics in the 4th quarter valued at approximately $2,861,000. RA Capital Management L.P. purchased a new stake in Monopar Therapeutics in the 4th quarter worth approximately $11,247,000. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in shares of Monopar Therapeutics during the 4th quarter valued at $13,182,000. Hedge funds and other institutional investors own 1.83% of the company's stock.

Insider Transactions at Monopar Therapeutics

In other news, major shareholder Tactic Pharma Llc sold 33,334 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $35.00, for a total value of $1,166,690.00. Following the completion of the sale, the insider now directly owns 822,255 shares of the company's stock, valued at approximately $28,778,925. This represents a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 20.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on MNPR. Piper Sandler reaffirmed an "overweight" rating and issued a $76.00 price target on shares of Monopar Therapeutics in a research note on Wednesday, March 19th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price target on shares of Monopar Therapeutics in a research note on Tuesday, April 1st. Finally, Jones Trading reissued a "hold" rating on shares of Monopar Therapeutics in a research note on Wednesday, April 2nd.

Monopar Therapeutics Price Performance

Shares of MNPR stock traded down $0.26 on Monday, hitting $36.90. The company's stock had a trading volume of 14,150 shares, compared to its average volume of 359,387. The stock has a market capitalization of $225.64 million, a price-to-earnings ratio of -18.73 and a beta of 1.11. Monopar Therapeutics Inc. has a fifty-two week low of $1.72 and a fifty-two week high of $54.30. The firm's fifty day moving average price is $37.50 and its 200-day moving average price is $31.87.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.27. Analysts predict that Monopar Therapeutics Inc. will post -1.65 EPS for the current fiscal year.

Monopar Therapeutics Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.